Plasma visfatin, a possible prognostic marker in aneurysmal subarachnoid hemorrhage

Visfatin is linked to inflammation and associated with clinical outcomes of intracerebral hemorrhage. This study was designed to investigate whether visfatin might serve as a marker of severity and prognosis in aneurysmal subarachnoid hemorrhage. In this study, plasma visfatin levels of 172 consecutive patients and 172 sex and age-matched healthy subjects were determined using enzyme-linked immunosorbent assay. The recorded clinical outcomes included in-hospital mortality and 6-month mortality and unfavorable outcome (Glasgow Outcome Scale score of 1-3). Plasma visfatin level was substantially higher in patients than in healthy controls (92.1 +/- 20.5 ng/mL vs. 12.4 +/- 3.2 ng/mL; P < 0.001), was significantly associated with the World Federation of Neurological Surgeons (WFNS) score (r = 0.569, P < 0.001) and Fisher score (r = 0.657, P < 0.001), was an independent predictor of in-hospital mortality [odds ratio (OR), 1.378; 95% confidence interval (CI), 1.036-1.866; P = 0.002] and 6-month mortality (OR, 1.261; 95% CI, 1.018-1.745; P = 0.004) and unfavorable outcome (OR, 1.207; 95% CI, 1.012-1.682; P = 0.008) in multivariate logistic regression analysis and had high predictive value for in-hospital mortality [area under curve(AUC), 0.849; 95% CI, 0.787-0.899; P < 0.001] and 6-month mortality (AUC, 0.868; 95% CI, 0.808-0.915; P < 0.001) and unfavorable outcome (AUC, 0.859; 95% CI, 0.797-0.907; P < 0.001) using receiver operating characteristic curves. AUCs of visfatin were similar to those of WFNS score and Fisher score (all P > 0.05), but visfatin did not improve the predictive values of WFNS score and Fisher score (all P > 0.05). Thus, visfatin may be associated with clinical severity of aneurysmal subarachnoid hemorrhage and also have prognostic value for clinical outcomes. (C) 2013 Elsevier Inc. All rights reserved.